Brief-Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
XLV•Ascletis Pharma begins U.S. Phase I study for ASC36 oral tablets
Sept. 8 (Reuters) - Ascletis Pharma Inc. 1672.HK:
- Initiates U.S. Phase I study for ASC36 oral tablets for obesity
- Receives IND clearance from the U.S. FDA for ASC36 oral tablets
Further company coverage: 1672.HK
